ERBB2 and breast carcinoma: Although activating HER2 mutations are found in ∼2-6% of HER2-amplified breast cancers (www.cbioportal.org; [78, 108]) whether they promote resistance to HER2-targeted therapy in HER2-amplified breast cancer has not yet been clearly established.